Microbiology Testing Market Overview
The Microbiology Testing Market will reach a CAGR of 10.4 % and a value of USD 5409.16 Million by 2027 in the forecast period.
Increasing rates of chronic and acute diseases worldwide are paving the way for market growth. In other words, the increase and outbreaks and epidemics of HIV, malaria, tuberculosis, and pneumonia directly impact market growth.
The higher spending rate on R & D skills, especially in developed and developing countries related to medical devices and devices, will create more favorable market growth opportunities. Research and development capabilities for integrating advanced technologies into healthcare facilities and detecting infectious diseases also support market growth.
The increase in funding from the federal government is aimed at driving the Microbiology Testing Market growth. In addition, the growth and expansion of the healthcare industry, driven by both public and private players, will create favorable market growth opportunities, especially in developing countries. The high rate of return on investment secured by research activities also positively affects the Microbiology Testing Market.
COVID-19 Analysis: The rising prevalence of COVID-19 is projected to influence market growth over the forecast period. As the coronavirus outbreak continues, the majority of pharmaceutical companies experienced a significant loss, thereby hampering the microbiology testing market. Revenue losses, temperature checks, emergency loans, and remote working are the new normal for pathology practices in dealing with the COVID-19 pandemic. Lack of testing or inadequate testing has been an issue since the beginning of the outbreak, initially due to the actual absence of authorized tests and later because of a shortage of supplies needed to conduct tests.On the manufacturer's side, a surge in demand for assay reagents, diagnostic kits, equipment, and services has been observed. For instance, Thermo Fisher Scientific predicts COVID-19 testing could create a USD 750 million tailwind in its second-quarter filing. In the first quarter of 2020, its laboratory products and services segment revenue grew 9% to USD 2.73 billion, compared with the revenue of USD 2.51 billion in the first quarter of 2019. Moreover, several policy changes were made owing to the COVID-19. These new government policies in improving the diagnostic and testing processes will eventually lead to the growth of microbiology testing as it is an essential component in the testing of viruses.Market Dynamics:Market DriversIncreasing number of infectious diseases, including COVID-19According to the WHO, three infectious diseases were ranked in the top ten causes of death worldwide in 2016, including lower respiratory infections, diarrheal diseases, and tuberculosis. Thus, the rising prevalence and incidence of infectious diseases drives the demand for microbiology testing, resulting in the growth of the global market. Moreover, the increasing cases of COVID-19 also contribute to the growth of the market.
- Government and private funds andfunding for R&D
Growing government and private funds and support for research and development further drive the growth of the market. For instance,the Department of Science and Technology (DST), India, announced funding of approximately USD 26.42 million to many scientific institutions, startups, and industries to build innovative solutions to fight the COVID-19 pandemicon 8 April 2020. These solutions include rapid and accurate diagnosis kits (paper-based and other point-of-care devices), protection equipment, and other necessary solutions and areanticipated to boost the demand for microbiology testing.
- Rising number of approvals and product launches
Several prominent players operating in the market are focusing on getting regulatory approvals and product launches to strengthen their position in the market. For instance, in April 2019, Bruker, an American manufacturer of scientific instruments, launched new assays, software, and library extensions for its MALDI Biotyper, IR Biotyper, and Fluorocycler XT product lines for microbial testing, infection control, and molecular diagnostics of infectious diseases.Market Restraints
- Limited reimbursement in developing regions
In most countries, delayed reimbursement acts as a key barrier to market growth. Reimbursement for microbiology testing is a complex process. The complexity in the reimbursement process itself acts as a challenge for this market.Also, the lack of standardized reimbursement policies in different countries limits the growth of the market. Thus, the lack of reimbursement in developing countries hampers market growth.
- Lack of accuracy of tests
Studies have found that testing kits and devices can show false-negative results.Owing to various reasons, the microbial testing kits often lack accuracy. This lack of accuracy of microbiology testing is anticipated to restraint the growth of the market.Market Opportunities
- Collaboration of major players with small players
The global microbiology testing market has numerous well-known players, such as Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Roche Diagnostics, and Danaher. Apart from these, other players are also actively collaborating with small players to invest in their innovative technologies and launch new infectious disease tests in the market. For instance, CSL Behring, a US biotherapeutics company, and South Dakota-based SAB Therapeutics are working together for clinical trials of its antibody-based treatment SAB-185 on COVID-19 patients. Likewise, the increasing collaboration of major players with small players is anticipated to provide significant growth opportunities for the market. Global Microbiology TestingMarketShare, by Product Type, 2019 (%)Source: MRFR Analysis Value Chain Analysis / Technology Analysis / Regulatory ImplicationsThe value chain analysis for the microbiology testing industry comprises five major components that start with the research & product development followed by manufacturing the products, distribution, sales, and post-sales services.The key market players focus on incorporating innovations in their current techniques to keep any discrepancies at bay. For instance, in July 2017, BD (Becton, Dickinson and Company), a leading global medical technology company, launched a new technology that can automatically report and release negative urine cultures.Segment OverviewThe global microbiology testing market has been divided based on product type, type of test, application, and end user.By product type
The consumables segment is further segmented into reagents, kits, and others. Chemicals and reagents are crucial elements of any research. Different kinds of chemicals and reagents are used in microbiology testing. Laboratory consumables and accessories like Petri dishes, bottles, containers, PCR consumables, tubes, pipettes, and many others are an essential part of routine laboratory practices.
The instruments segment is further divided into microbiology analyzers, automated microbiology instruments, and others. Advanced instruments play a very important role in the development and management of microorganisms for research. The instruments include laboratory instruments, microbiology analyzers, and dispensers.By type of testOn the basis of type of test, the market is bifurcated into bacterial, viral, fungal, and others.The bacterial testing type accounts for the largest share and is anticipated to register a CAGR of 9.82% from 2020 to 2027.
Bacterial testing type accounts for the largest share due to the increasing prevalence of infections due to bacterial pathogens and the rise in guidelines streamlining the process of Antimicrobial Susceptibility Testing (AST).
Viral infections accounted for a significant share due to the outbreak of coronavirus all over the globe. Owing to the increasing prevalence of viral infection and outbreaks, there is a significant demand forviral infection screening.This drives the growth of the market
Fungal diseases are often caused by fungi commonly found in the environment. The National Center for Biotechnology Information (NCBI), in 2017, stated that nearly a billion people are estimated to have skin, nail, and hair fungal infections, which have a significant impact on their lives or are fatal.By ApplicationOn the basis of application, the market is segmented into gastrointestinal (GI) infections, respiratory infections, Urinary Tract Infections (UTI), sexually transmitted infections, and others. The gastrointestinal infections segment accounts for the largest share and is projected to reach USD 3,222.42 million by the end of 2027, owing to the increasing number of patients suffering from gastrointestinal infections and rising healthcare expenditure.
- Gastrointestinal Infections
According to the National Center for Biotechnology Information (NCBI), gastrointestinal infections in the US have consistently been among the most frequent diseases.
Respiratory infections are the most common and rapidly growing type of infection. These infections are classified into two major types, i.e., upper and lower acute respiratory infections. Upper acute respiratory diseases are mild and mostly caused by viruses.
UTI infections are on the rise among young women. For instance, according to the NCBI in 2016, around 50–60% of women are likely to experience a UTI in their lifetime, and the estimated number of UTIs per person per year is 0.5 in young females.
- Sexually Transmitted Infections
According to the WHO, more than 1 million Sexually Transmitted Infections (STIs) are acquired every day worldwide. This high rate of sexually transmitted infections drives the market growth. By End UserOn the basis of end user, the market is bifurcated into hospital-associated laboratory, independent laboratory, academic and research institutes, and others. The hospital-associated laboratory segment accounted for the largest market share with a value of USD 1,337.84 million in 2019 due to the increasing inclination toward realizing importance of accurate diagnosis, and testing prompts the demand for microbiology testing in the laboratories.
- Hospital Associated Laboratory
Hospital-associated laboratories act as a support to the clinical services offered at the hospital. The specific services offered by hospital-associated labs include anatomic (surgical pathology, cytopathology, and autopsy) and clinical (laboratory medicine) testing.
Independent laboratories are private and commercial facilities that conduct high volume and also specialty (high complexity and/or rare) laboratory testing. Most of these tests are referred by physicians, hospital facilities, and other patient care facilities such as nursing homes.
- Academic and Research Institutes
The rise in infectious diseases pushes the demand for testing in academic and research institutes. These institutions are continuously involved in research activity to best diagnose a certain micro-organism.
The others segment includes diagnostic centers and path labs affiliated withambulatory centers.Global Microbiology TestingMarket Share, by Region, 2019 (%) Source: MRFR AnalysisRegional AnalysisThe global microbiology testing market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and Middle East & Africa.Americas: The Americas is expected to command the largest market share due to a well-developed healthcare sector, rising prevalence and incidence rate of infectious diseases, and the presence of leading players. In addition, the rise in strategic initiatives employed by major players is boosting the demand for microbiology testing in the region. For instance, in April 2020, Bio-Rad Laboratories, Inc. acquired Celsee, Inc., a company based in the US that offers instruments and consumables for the isolation, detection, and analysis of single cells.Europe: Europe accounted for a substantial share in the global microbiology testing market.This can be attributed to the increasing support from the government, the presence of a huge geriatric population, and high healthcare spending.Also, the players are partnering up with public and private institutions to create awareness regarding microbiology testing advancements. For instance, in December 2019, BioMérieux (France) was selected as a supplier in a tender process by the Fleming Fund, a USD 333 million (pound 265 million) aid investment to tackle antimicrobial resistance in low middle-income countries around the world.Asia-Pacific:Asia-Pacific is expected to be the fastest-growing market in microbiology testing, mainly due to increasing funding for R&D, developing healthcare infrastructure, increasing awareness about microbiology testing, government initiatives, and support to improve public health and huge investment by companies. Thus, owing to these factors, Asia-Pacific is lucrative for the microbiology testing market.Middle East & Africa:The microbiology testing market in Middle East & Africa is growing dramatically due to the increasing prevalence of various infectious diseases like Ebola. Moreover, sexually transmitted diseases are also a major public health concern in this region. The Middle East region is growing significantly as compared to Africa. Factors affecting the microbiology testing market in this region are limited access to healthcare facilities, lack of knowledge of new microbiology testing techniques, less funding in R&D, and limited availability of products.Competitive LandscapeThe microbiology testing market is profitable, both for existing players as well as new entrants. A substantial level of rivalry is observed among the existing manufacturers in the market. Our analysis revealed that market players have adopted different strategies and innovative research and development techniques to expand their business and secure their global microbiology testing market position. For instance, in July 2020, bioMérieux launched BIOFIRE MYCOPLASMA, an innovative test for mycoplasma detection in pharmaceutical products used for biotherapeutics (antibodies, hormones, cell and gene therapies, etc.), the most vibrant sector in the pharmaceutical industry. The new BIOFIRE MYCOPLASMA test, which is available in the United States, is expected to be launched in some countries in Europe and the Asia-Pacific region. Furthermore, in May 2020, Beckman Coulter launched DxH 690T hematology analyzer in the U.S. DxH 690T provides all of the benefits of the company’s flagship DxH 900 large-volume hematology analyzer in a table-top configuration. Commercially available worldwide, the DxH 690T builds on Beckman Coulter’s strength and history in hematology innovation and complements its broad hematology portfolioBeckman Coulter, Inc. has the robust industry experienceand is one of the leading companies in the microbiology testing market. Furthermore,a high customer satisfaction level, exceptional performance in new markets, and a strong product portfolio add to the company’s competitive advantage. The company also has a strong clientele and is well established in the industry. Also, it is continuously involved in seminars, conferences, and trade fairs in several countries to generate awareness about its products. Beckman Coulter works as a subsidiary of Danaher Corporation.List of Key Companies Covered in this report:
- BioMérieux SA (France)
- Beckman Coulter, Inc. (US)
- Bio-Rad Laboratories, Inc. (US)
- Hoffmann-La Roche Ltd (Switzerland)
- Merck KGaA(Germany)
- Thermo Fisher Scientific Inc. (US)
- Qiagen (Germany)
- Shimadzu Corporation (Japan)
- Agilent Technologies Inc. (US)
- Bruker (US)
In June 2022
STEMart, a provider of integrated medical device CRO services dedicated to the clinical development of medical devices and diagnostics, presents comprehensive microbiology and sterility testing of sterile pyrogen-free products. With extensive microbiology and fertility testing expertise, STEMart continues to provide a full-service experience to help manufacturers meet regulatory goals and mitigate compliance risks.
In July 2022
EMSL Analytical, Inc. announced that its Houston laboratory offers PCR tests for the genera Bacteroides and Legionella genera. Polymerase chain reaction (PCR) is a technique for "amplifying" small segments of DNA. The Houston Institute specializes in microbiological testing involving molds, bacteria, wastewater-borne pollutants, E. Coliforms, total coliforms, food pathogens, etc.
In June 2020
Bio Mérieux has launched BIOFIRE MY COPLASMA, an innovative test for detecting mycoplasma in pharmaceuticals used in biotherapy (antibodies, hormones, cells, gene therapy, etc.), which is the most dynamic area of the pharmaceutical industry. The new BIOFIRE MYCOPLASMA test available in the United States will be rolled out in Europe and some countries in the Asia Pacific within the next few months.
Report Overview: The study covers the existing short-term and long-term market effect, helping decision-makers to draught short-term and long-term plans for businesses by region. The report covers major regions in the Americas, Europe, Asia-Pacific, and Middle East & Africa. The report analyzes market drivers, restraints, opportunities, challenges, Porter's Five Forces, Value Chain, and impact of COVID-19 on the market. Scope of the Report & Segmentation Global Microbiology Testing Market, by Product Type
- Microbiology Analyzers
- Automated Microbiology Instruments
Global Microbiology Testing Market, by Type of Test
Global Microbiology Testing Market, by Application
- Gastrointestinal Infections
- Respiratory Infections
- Urinary Tract Infections
- Sexually Transmitted Infections
Global Microbiology Testing Market, by End User
- Hospital Associated Laboratory
- Independent Laboratory
- Academic and Research Institutes
Global Microbiology Testing Market, by Region
- Rest of Latin America
- Western Europe
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
Middle East & Africa